Note from the publisher: Reader survey

Publisher's Note:

FiercePharma launched a little over four weeks ago with the goal of creating a one-stop resource to connect you with the news, information and analysis shaping the pharmaceutical industry. We've already signed up 8,000 subscribers to the email publication and thousands more are reading us via the website and RSS feeds. Thanks for being a part of this fast growing community!

While we are proud of the progress, we know that there is still work to do. Your feedback is critical as we continue to refine FiercePharma's editorial coverage and scope. Later this afternoon, you'll receive a short survey that should take less than three minutes to complete. I hope you'll take the time to help us make FiercePharma even more valuable to you.

In the meantime, please feel free to send any story ideas, inside tips, press releases or media requests to our editors--Tracy Staton and Maureen Martino.

If you are interested in learning about sponsorship opportunities in the newsletter, website, or one of our upcoming webinars, please contact Arsalan Arif.

We look forward to your feedback!

Thanks,
Sean Griffey
Publisher, FiercePharma

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.